Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Aanchal Sugandh

DARK SECRETS: What are wall street analysts target price for biogen stock | Vintage Vibes

Headquartered in Cambridge, Massachusetts, Biogen Inc. (BIIB) researches, develops, and commercializes therapies for severe neurological, immunological, and rare disorders. Commanding a market cap of approximately $28.8 billion, its portfolio spans treatments for multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), and other debilitating conditions. 

Over the past 52 weeks, Biogen’s shares have appreciated 41.9%, substantially outperforming the S&P 500 Index ($SPX), which delivered an 11.8% gain over the same period. Year-to-date (YTD), BIIB stock is up another 11.7%, while the broader index has recorded a marginal decline.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.